罗格列酮对初诊2型糖尿病患者颈动脉内膜中层厚度的影响

目的 观察罗格列酮对初诊2型糖尿病患者颈动脉内膜中层厚度（IMT）的影响,探讨其对大血管的保护作用.方法 60例初诊2型糖尿病患者随机分为罗格列酮组和对照组,治疗12周后,高分辨超声测量IMT,并检测两组患者服药前后糖基化血红蛋白、血清胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆同醇.结果 与对照组比较,罗格列酮组IMT明显降低（P＜0.05）,两组治疗前后IMT值均具有显著差异.结论 罗格列酮能明显降低初诊2型糖尿病患者的IMT水平,可能延缓2型糖尿病患者动脉粥样硬化进展,从而改善2型糖尿病患者大血管并发症.

Effects of rosiglitazone on Intima-Medial Thickness of Carotid Artery in newly diagnosed type 2 diabetic patients

Objective To study the effects of pioglitazone on intima-medial thickness （IMT）of carotid artery in newly diagnosed type 2 diabetic mellitus （T2DM） patients. Methods T2DM patients （ n = 60） were divided into pioglitazone group （ n = 30 ） and placebo group （ n = 30 ） by the rule of random and double-blind. The IMT of carotid arterywas detected by B-mode ultrasound 3 months later. After 3 months treatment, HbA1 c, total cholesterol （ TC ） , tfiglyceride （ TG ） , low density lipoprotein cholesterol and high density lipoprotein cholesterol were measured. Results IMT of carotid artery in pioglitazone group was significantly lower than that in placebo group （ P 〈 0.01 ）. Conclusion Pioglitazone could significantly reduce IMT of carotid artery in newly diagnosed T2DM patients and have positive effects on improving vascular complications of T2DM patients.